Agios Pharmaceuticals (NASDAQ:AGIO) Trading Down 7.5% – Time to Sell?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)’s stock price dropped 7.5% during mid-day trading on Friday . The company traded as low as $33.06 and last traded at $33.22. Approximately 99,557 shares were traded during trading, a decline of 90% from the average daily volume of 1,016,120 shares. The stock had previously closed at $35.90.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on AGIO shares. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Leerink Partners cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Royal Bank of Canada upped their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Raymond James reiterated an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Finally, Scotiabank lifted their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $56.33.

Agios Pharmaceuticals Price Performance

The business has a fifty day moving average price of $46.77 and a two-hundred day moving average price of $45.50. The firm has a market cap of $1.92 billion, a PE ratio of 2.97 and a beta of 0.87.

Insider Activity

In other news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now directly owns 18,906 shares of the company’s stock, valued at $608,395.08. This trade represents a 12.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.93% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in AGIO. Farallon Capital Management LLC grew its position in Agios Pharmaceuticals by 1.1% in the second quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock worth $243,822,000 after acquiring an additional 63,900 shares in the last quarter. State Street Corp boosted its holdings in Agios Pharmaceuticals by 10.2% in the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after purchasing an additional 216,484 shares in the last quarter. Erste Asset Management GmbH acquired a new position in Agios Pharmaceuticals during the third quarter worth $97,199,000. Geode Capital Management LLC raised its holdings in Agios Pharmaceuticals by 0.5% during the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after buying an additional 6,101 shares in the last quarter. Finally, Marshall Wace LLP raised its holdings in Agios Pharmaceuticals by 307.8% during the second quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock valued at $48,887,000 after buying an additional 855,739 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.